12 results match your criteria: "UCSF MS Center[Affiliation]"
J Neurol Neurosurg Psychiatry
July 2024
Departments of Neurology, Tiantan Neuroimaging Center of Excellence, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Background: Although trigeminal nerve involvement is a characteristic of multiple sclerosis (MS), its prevalence across studies varies greatly due to MRI resolution and cohort selection bias. The mechanism behind the site specificity of trigeminal nerve injury is still unclear. We aim to determine the prevalence of trigeminal nerve involvement in patients with MS in a consecutive 7T brain MRI cohort.
View Article and Find Full Text PDFLancet Neurol
December 2021
UCSF MS Center, Weill Institute of Neuroscience, San Francisco, CA, USA.
BMC Med Genomics
July 2021
Centre de Recherche en Transplantation Et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.
Background: To study the accumulation of MS-risk resulting from different combinations of MS-associated conserved-extended-haplotypes (CEHs) of the MHC and three non-MHC "risk-haplotypes" nearby genes EOMES, ZFP36L1, and CLEC16A. Many haplotypes are MS-associated despite having population-frequencies exceeding the percentage of genetically-susceptible individuals. The basis of this frequency-disparity requires explanation.
View Article and Find Full Text PDFNeurology
May 2019
From the UCSF MS Center (E.W.), San Francisco, CA; The Children's Hospital of Philadelphia (B.B.), Perelman School of Medicine, University of Pennsylvania; Birmingham Children's Hospital (E.W.), UK; Department of Health Sciences (M.-P. S.), University of Genova and Ospedale Policlinico San Martino IRCCS; Department NEUROFARBA (M.-P.A.), University of Florence, Italy; IRCCS Fondazione Don Carlo Gnocchi (M.-P.A.), Florence, Italy; Department of Neurology (R.H.), Erasmus MC, Rotterdam, the Netherlands; MS Comprehensive Care Center at NYU Langone (L.K.), New York, NY; Division of Paediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Datteln, Germany; Pediatric MS Center (S.T.), Department of Neurology, National Pediatric Hospital Dr. Garrahan, Buenos Aires, Argentina; and Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Boston.
Objective: The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety.
Methods: The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the advent of clinical trials for this population.
Results: In the last few years, convincing evidence has emerged that the biological processes involved in MS are largely shared across the age span.
Neurology
October 2016
From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA.
Objective: To determine the association between hormone therapy (HT) and physical quality of life (QOL) in postmenopausal women with multiple sclerosis (MS).
Methods: We included female participants from the prospective Nurses' Health Study, with a diagnosis of definite or probable MS, who had completed a physical functioning assessment (PF10; subscale of the 36-Item Short-Form Health Survey QOL survey) at a time point between 3 and 10 years after their final menstrual period (early postmenopause). We assessed the association between HT use at this time point (never vs at least 12 months of systemic estrogen with/without progestin) and both PF10 and the 36-Item Short-Form Health Survey Physical Component Scale.
BMC Neurol
April 2016
Department of Neurology, UCSF MS Center, University of California, San Francisco, 675 Nelson Rising Lane, Suite #221D, San Francisco, CA, 94158, USA.
Background: Epidemiological observations regarding certain population-wide parameters (e.g., disease-prevalence, recurrence-risk in relatives, gender predilections, and the distribution of common genetic-variants) place important constraints on the possibilities for the genetic-basis underlying susceptibility to multiple sclerosis (MS).
View Article and Find Full Text PDFJ Med Genet
September 2015
Department of Neurology, University of California, San Francisco, San Francisco, California, USA UCSF MS Center, University of California, San Francisco, San Francisco, California, USA.
Genome-wide association studies (GWAS), using single nucleotide polymorphisms (SNPs), have yielded 110 non-human leucocyte antigen genomic regions that are associated with multiple sclerosis (MS). Despite this large number of associations, however, only 28% of MS-heritability can currently be explained. Here we compare the use of multi-SNP-haplotypes to the use of single-SNPs as alternative methods to describe MS genetic risk.
View Article and Find Full Text PDFNeurohospitalist
April 2014
UCSF MS Center, Department of Neurology, San Francisco, CA, USA.
Rapid advances are occurring in multiple sclerosis disease modifying therapies. Recent therapeutic advances include modifications to improve tolerability of existing products (e.g.
View Article and Find Full Text PDFInt MS J
March 2008
UCSF MS Center, 350 Parnassus Street, Suite 908, San Francisco, California 94117, USA.
Immune modulators, such as interferon beta and glatiramer acetate, have focused on T-cells as the primary therapeutic target, although both drugs affect other cell types as well. There has been a renewed interest in the potential roles of both antibody-dependent and antibody-independent B-cell responses in multiple sclerosis (MS) and its animal model. Accumulating data suggest that the contribution of B-cells and their secreted products to central nervous system (CNS) inflammatory diseases may relate to the abilities of B-cells to (1) differentiate into plasmocytes that produce antibodies, (2) function as antigen-presenting cells, contributing to Tcell activation, (3) produce effector cytokines that may modulate the local immune environment, (4) harbour the Epstein Barr virus in a chronically activated state, and (5) play a role in formation and maintenance of new lymphoid foci within the CNS.
View Article and Find Full Text PDFRev Neurol (Paris)
June 2007
UCSF MS Center, University of California-San Francisco, 350 Parnassus Street, San Francisco, CA 94117, USA.
Immune modulators, such as interferon beta (IFNB) and glatiramer acetate (GA), have focused on T cells as the primary therapeutic target. In the past few year several novel therapeutic strategies have emerged that will be reviewed here. These include treatments that modify the immune balance in general, others that inhibit more specifically various key players of the immune response such as antibody-dependent, and antibody-independent B cell responses in MS, but also some that inhibit migration of inflammatory cells to the central nervous system (CNS).
View Article and Find Full Text PDFExpert Opin Emerg Drugs
May 2003
UCSF MS Center, 350 Parnassus Street, Suite 908, San Francisco, CA 94117, USA.
Multiple sclerosis (MS), the most common central nervous system (CNS) demyelinating disease, is thought to be mediated in part by CNS autoantigen-specific T cells. The aetiology of the disease is unclear, but includes genetic and environmental factors. The disease onset often occurs in young adults and is characterised by bouts of neurological symptoms such as numbness, weakness, imbalance or visual difficulties that may not be recovered from.
View Article and Find Full Text PDFNeurology
July 2003
UCSF MS Center, San Francisco, CA 94117, USA.
Objective: To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders.
Methods: Data on all patients who received IFNB who were entered in the prospective European Database for Multiple Sclerosis (EDMUS) database in Lyon as of March 31, 2001, were reviewed. Responders were defined as having a lower relapse rate on IFNB compared with the year or 2 years prior to IFNB therapy.